Skip to main content

Marina Closes Cequent Facility, Consolidates R&D in Washington

Premium

Marina Biotech announced last week that it has closed its Cambridge, Mass., operations and is consolidating all of its research and development activities at its Bothell, Wash. headquarters.

The company acquired the Massachusetts facility through its 2010 acquisition of Cequent Pharmaceuticals (GSN 4/1/2010).

Marina said that the move would not affect development of Cequent's transkingdom RNAi technology, which will continue in Washington, and that its phase I program for CEQ508, a tkRNA-based treatment for familial adenomatous polyposis, will be unchanged.

Marina President and CEO Michael French said in an e-mail that the company transitioned three positions from the Cambridge facility to Bothell, but added that certain positions associated with maintaining the bacterial component of the tkRNA technology were not relocated since Marina already has that core capability in Washington.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.